Printer Friendly

Meridian Bioscience updates net revenues and fiscal 2016 earnings guidance.

M2 EQUITYBITES-September 10, 2015-Meridian Bioscience updates net revenues and fiscal 2016 earnings guidance

(C)2015 M2 COMMUNICATIONS http://www.m2.com

Life science company Meridian Bioscience (NasdaqGS:VIVO) on Wednesday provided fiscal 2016 net revenues and earnings estimates for the fiscal year ending 30 September 2016, based on its business planning and budgeting activities.

Meridian Bioscience's management expects net revenue growth of 3% to 5% on a constant currency basis, a net revenue range of USD195m to USD200m and per share diluted earnings to be between USD0.86 and USD0.90, which assume an increase in average diluted shares outstanding from 42.1m at fiscal 2015 year end to 42.2m at fiscal 2016 year end.

In conjunction, the company expects the net revenues and earnings guidance from expected internal growth and does not include net revenue from new products expected to be launched in 2016, or the impact of any acquisitions the Company might complete during fiscal 2016.

According to the company, its management expects net revenue and earnings in fiscal 2015 to be near the low end of the guidance range. The impact of foreign currency exchange rates assumed in our guidance versus those actually experienced, is estimated to have had a negative impact of over USD3m on net revenues.

For fiscal 2015, the management expects net revenue of USD193m and USD0.85 per share diluted earnings.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Article Type:Financial report
Date:Sep 10, 2015
Words:240
Previous Article:Rockwell Medical unveils US FDA approved Triferic in US to maintain hemoglobin concentration in hemodialysis patients.
Next Article:Dr. Reddy's to market DiaResQ for pediatric infectious diarrhea.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters